Tweet
I used Lexogen's 3' Quantseq kit and mistakenly used the wrong bead amount for the first cDNA purification (30 ul beads instead of 16). My guess is that resulted in libraries with lower fragment size distribution than I normally see, and several libraries have obvious peaks around 150 bp indicating likely adapter dimer (see attached trace). I was hoping to sequence these libraries with 75 bp SR on Next-seq. What should I expect to get out of the sequencing run if I proceed? I am contemplating trying Ampure Xp purification, but the libraries are already small (most around 300 bp average, or less). So I don't know how it would work. I have some reads to burn so it would be ok if I lost some to adapter dimer (maybe even as much as 30% or 40%). But if most the reads would be lost, I would probably just remake the libraries.
-
-
Dear QuantSeq kit user, please send these details to [email protected], and our technical support will reply ASAP.
Thank you,
Lukas Paul
Sr. Manager Scientific Affairs
Lexogen GmbH
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment